LPCN Lipocine Corporation: Rasio rega marang prakiraan pendapatan
Lipocine Inc. minimizes operational threats through a diversified portfolio of drugs for endocrine and neurological therapy. The forward P/S trajectory reflects market expectations, where the 4.80 mark serves as a current indicator. High R&D expenditures in the field of steatohepatitis create financial pressure, yet unique lipid delivery systems and patent protection establish a significant barrier to entry for competitors.
Ringkesan rincian data analitis Lipocine Corporation (LPCN)
- rega pasar lan target rega analis:
- data kapitalisasi saham perusahaan:
- indikator nilai buku ekuitas:
- rincian struktur utang lan likuiditas bisnis:
Utang marang Ekuitas Lipocine Inc.|LPCN - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Lipocine Inc.|LPCN - Utang perusahaan|Utang-utang marang kapitalisasi buku Lipocine Corporation|LPCN - Gunggunge utang jangka dawa|Utang jangka cendhak perusahaan Lipocine|Likuiditas cepet lipocine.com
- rincian asil keuangan lan kelipatan valuasi:
LPCN - Penghasilan resik perusahaan|Proyeksi bathi mangsa ngarep Lipocine Inc.|LPCN - Koefisien rega marang bathi|Pangali Forward P/E Lipocine Corp|LPCN - Kapitalisasi marang bathi resik kanthi nimbang wutah|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Lipocine Corporation|LPCN - Bathi operasional sadurunge amortisasi|Bathi resik saben saham (EPS TTM) Lipocine|LPCN - Bathi resik saben siji saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan lipocine.com|LPCN - Tambahing bathi saben saham ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Lipocine Inc.
- indikator volume dodolan lan pendapatan:
Ringkesan analitik perusahaan:Lipocine LPCN
The forward P/S ratio determines the market value of one dollar of expected revenue, allowing investors to track the dynamics of revenue expectations in real time. By analyzing the forward P/S multiple, one can diagnose whether an asset is overheated or if the potential of Lipocine Inc. (LPCN) in developing innovative oral drug delivery systems for the therapy of endocrine pathologies is undervalued.
Analisis perusahaan pesaing
Rasio rega marang prakiraan pendapatan Ascendis Pharma ASND|Madrigal Pharmaceuticals Inc (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake|Crinetics Pharmaceuticals, Inc. (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan NewAmsterdam Pharma N.V. (NAMS)|Multiplikator forward rega marang pendapatan Soleno Therapeutics Corp SLNO|Rasio rega marang prakiraan pendapatan Amicus Therapeutics FOLD|89bio.com - Rasio rega marang prakiraan pendapatan|Agios Pharmaceuticals, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake Structure Therapeutics Inc GPCR|MiMedx Group (MDXG) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan RZLT (Rezolute Bio)|Rasio rega marang prakiraan pendapatan Lexicon Pharmaceuticals|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep mbxbio.com MBX|Multiplikator Forward P/S ALT|Multiplikator forward rega marang pendapatan Aardvark Therapeutics Inc. AARD|Multiplikator Forward P/S SGMT (Sagimet)|Rasio kapitalisasi marang dodolan sing dikarepake BioAge Labs, Inc (BIOA)|BMEA - Rasio rega marang prakiraan pendapatan|QNCX (Quince Therapeutics) - Kapitalisasi marang prakiraan pendapatan|GUTS: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep vTv Therapeutics (VTVT)|Multiplikator forward rega marang pendapatan ATPC|PLUR: Rega forward marang dodolan|Multiplikator Forward P/S SYBX|Rasio kapitalisasi marang dodolan sing dikarepake matinasbiopharma.com|Rasio rega marang prakiraan pendapatan Spruce Biosciences, Inc. SPRB|GLTO: Kapitalisasi marang prakiraan pendapatan|Carmell Corp - Multiplikator Forward P/S|Lumos Therapeutics (LUMO) - Multiplikator forward rega marang pendapatan|ONVO (Organovo Holdings, Inc.) - Multiplikator forward rega marang pendapatan|RDUS - Rasio kapitalisasi marang dodolan sing dikarepake
